Clinical Characteristics of the Subjects With FT1DM and Nondiabetic Controls
| Case Subject . | Age, y . | Sex . | Duration of Diabetes, d . | GADAb, U/mL/ICA, JDF U . | Pancreatic Weight, g . | Blood C-Peptide, ng/mL . | Serum Elastase I, ng/mL . | BMI, kg/m2 . | Treatment of Diabetes . | Noninsulin Requiring Period, y . | Cause of Death . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FT1DM | |||||||||||
| FT-1 | 14 | M | 5 d | Negative/negative | nd | <0.02 | — | nd | Insulin | 0 | DKA |
| FT-2 | 25 | M | 2 d | Negative/nd | nd | <0.02 | 679a | nd | Insulin | 0 | DKA |
| FT-3 | 29 | M | 2 d | Negative/nd | nd | <0.02 | — | nd | Insulin | 0 | DKA |
| Mean ± SD | 23 ± 8 | M/F: 3/0 | 3 ± 2 | Negative | nd | 0 | — | nd | 0 | ||
| Range | 14–29 | 2-5 | |||||||||
| Non-DC | |||||||||||
| ND-1–17b | — | — | |||||||||
| Mean ±SD | 66 ± 7 | M/F: 9/8 | — | Negative/nd | 78.8 ± 9.2 | nd | — | 21.5 ± 3.0 | — | ||
| Range | 53–74 | 63.1–95.1 | 16.4–27.3 | — | — | See text |
| Case Subject . | Age, y . | Sex . | Duration of Diabetes, d . | GADAb, U/mL/ICA, JDF U . | Pancreatic Weight, g . | Blood C-Peptide, ng/mL . | Serum Elastase I, ng/mL . | BMI, kg/m2 . | Treatment of Diabetes . | Noninsulin Requiring Period, y . | Cause of Death . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FT1DM | |||||||||||
| FT-1 | 14 | M | 5 d | Negative/negative | nd | <0.02 | — | nd | Insulin | 0 | DKA |
| FT-2 | 25 | M | 2 d | Negative/nd | nd | <0.02 | 679a | nd | Insulin | 0 | DKA |
| FT-3 | 29 | M | 2 d | Negative/nd | nd | <0.02 | — | nd | Insulin | 0 | DKA |
| Mean ± SD | 23 ± 8 | M/F: 3/0 | 3 ± 2 | Negative | nd | 0 | — | nd | 0 | ||
| Range | 14–29 | 2-5 | |||||||||
| Non-DC | |||||||||||
| ND-1–17b | — | — | |||||||||
| Mean ±SD | 66 ± 7 | M/F: 9/8 | — | Negative/nd | 78.8 ± 9.2 | nd | — | 21.5 ± 3.0 | — | ||
| Range | 53–74 | 63.1–95.1 | 16.4–27.3 | — | — | See text |
Clinical Characteristics of the Subjects With FT1DM and Nondiabetic Controls
| Case Subject . | Age, y . | Sex . | Duration of Diabetes, d . | GADAb, U/mL/ICA, JDF U . | Pancreatic Weight, g . | Blood C-Peptide, ng/mL . | Serum Elastase I, ng/mL . | BMI, kg/m2 . | Treatment of Diabetes . | Noninsulin Requiring Period, y . | Cause of Death . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FT1DM | |||||||||||
| FT-1 | 14 | M | 5 d | Negative/negative | nd | <0.02 | — | nd | Insulin | 0 | DKA |
| FT-2 | 25 | M | 2 d | Negative/nd | nd | <0.02 | 679a | nd | Insulin | 0 | DKA |
| FT-3 | 29 | M | 2 d | Negative/nd | nd | <0.02 | — | nd | Insulin | 0 | DKA |
| Mean ± SD | 23 ± 8 | M/F: 3/0 | 3 ± 2 | Negative | nd | 0 | — | nd | 0 | ||
| Range | 14–29 | 2-5 | |||||||||
| Non-DC | |||||||||||
| ND-1–17b | — | — | |||||||||
| Mean ±SD | 66 ± 7 | M/F: 9/8 | — | Negative/nd | 78.8 ± 9.2 | nd | — | 21.5 ± 3.0 | — | ||
| Range | 53–74 | 63.1–95.1 | 16.4–27.3 | — | — | See text |
| Case Subject . | Age, y . | Sex . | Duration of Diabetes, d . | GADAb, U/mL/ICA, JDF U . | Pancreatic Weight, g . | Blood C-Peptide, ng/mL . | Serum Elastase I, ng/mL . | BMI, kg/m2 . | Treatment of Diabetes . | Noninsulin Requiring Period, y . | Cause of Death . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FT1DM | |||||||||||
| FT-1 | 14 | M | 5 d | Negative/negative | nd | <0.02 | — | nd | Insulin | 0 | DKA |
| FT-2 | 25 | M | 2 d | Negative/nd | nd | <0.02 | 679a | nd | Insulin | 0 | DKA |
| FT-3 | 29 | M | 2 d | Negative/nd | nd | <0.02 | — | nd | Insulin | 0 | DKA |
| Mean ± SD | 23 ± 8 | M/F: 3/0 | 3 ± 2 | Negative | nd | 0 | — | nd | 0 | ||
| Range | 14–29 | 2-5 | |||||||||
| Non-DC | |||||||||||
| ND-1–17b | — | — | |||||||||
| Mean ±SD | 66 ± 7 | M/F: 9/8 | — | Negative/nd | 78.8 ± 9.2 | nd | — | 21.5 ± 3.0 | — | ||
| Range | 53–74 | 63.1–95.1 | 16.4–27.3 | — | — | See text |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
